Ads
related to: estrogen positive breast cancer postmenopausal women
Search results
Results From The WOW.Com Content Network
Because some breast cancers respond to estrogen, lowering estrogen production at the site of the cancer (i.e. the adipose tissue of the breast) with aromatase inhibitors has been proven to be an effective treatment for hormone-sensitive breast cancer in postmenopausal women. [3]
Fulvestrant is administered as an intramuscular injection and is indicated for the treatment of advanced breast cancer in postmenopausal women whose cancer has progressed following anti-estrogen therapy. As of 2016 the only marketed SERD was fulvestrant (brand name Faslodex). [1]
In postmenopausal women, the ovaries cease to be the main source of estrogen production, with estrogen being instead synthesized from regulatory steroid hormones called androgens in tissues of the bone, fat, and breast through the activity of the enzyme aromatase. [15]
In healthy cells, these receptors bind to estrogen and cause normal changes in breast tissue. Breast cancer tumors that are estrogen receptor-positive, or ER+, usurp this normal physiological ...
ER-positive is one of the Receptor statuses identified in the classification of breast cancer.Receptor status was traditionally considered by reviewing each individual receptor (ER, PR, her2) in turn, but newer approaches look at these together, along with the tumor grade, to categorize breast cancer into several conceptual molecular classes [1] that have different prognoses [2] and may have ...
It is used as endocrine therapy for women with estrogen or progesterone receptor-positive, stage 4 or recurrent metastatic breast cancer [7] and has demonstrated similar efficacy compared to tamoxifen as adjuvant treatment of breast cancer and in the treatment of metastatic breast cancer. [6]
Ads
related to: estrogen positive breast cancer postmenopausal women